<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>RATIONALE AND OBJECTIVES: Experiments were designed to (1) compare the effects of iodinated contrast media (CM) on a rat model of <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo>, (2) evaluate which element of the <z:chebi fb="0" ids="31718">ioxaglate</z:chebi> solution supports its antithrombotic activity, and (3) investigate the interaction of ionic and non-ionic CM with the antiplatelet agent <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>MATERIALS AND METHODS: Carotid <z:mp ids='MP_0005048'>thrombosis</z:mp> was induced in rats by extravascular application of a filter paper soaked in <z:chebi fb="0" ids="30810">FeCl3 </z:chebi>(35% vol/wt), proximal to an ultrasonic flow probe </plain></SENT>
<SENT sid="2" pm="."><plain>(1) The antithrombotic potential of low-osmolar ionic (<z:chebi fb="0" ids="31718">ioxaglate</z:chebi> Na/meglumine) or nonionic contrast media (<z:chebi fb="0" ids="31709">iohexol</z:chebi> and iodixanol) (<z:hpo ids='HP_0000001'>all</z:hpo> 1600 mg <z:chebi fb="60" ids="24859">iodine</z:chebi>/kg, IV) was assessed by measuring the time to occlusion (TTO) of the carotid artery and the <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> weight (TW) </plain></SENT>
<SENT sid="3" pm="."><plain>(2) Isotonic saline and iso-osmolar (280 mOsm/kg) and hyperosmolar (560 mOsm/kg) solutions of meglumine <z:chebi fb="16" ids="36807">hydrochloride</z:chebi>, meglumine <z:chebi fb="0" ids="31718">ioxaglate</z:chebi> (560 mOsm/kg), <z:chebi fb="199" ids="26708">sodium</z:chebi> <z:chebi fb="0" ids="31718">ioxaglate</z:chebi> (600 mOsm/kg) and <z:chebi fb="199" ids="26708">sodium</z:chebi> and meglumine <z:chebi fb="0" ids="31718">ioxaglate</z:chebi> (commercial solution) were tested under similar conditions </plain></SENT>
<SENT sid="4" pm="."><plain>(3) Interaction with <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> was tested by injecting lower dose of CM (960 mg <z:chebi fb="60" ids="24859">iodine</z:chebi>/kg) 2 hours after <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> (2 mg/kg per os) </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: (1) <z:chebi fb="0" ids="31718">Ioxaglate</z:chebi> prolonged TTO when compared with saline (30.0 +/- 1.1 minute vs. 19.6 +/- 2.4 minutes, P&lt; 0.001), whereas <z:chebi fb="0" ids="31709">iohexol</z:chebi> had no effect (21.3 +/- 1.3 minutes) </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="0" ids="31718">Ioxaglate</z:chebi>'s effect was associated with a reduction in TW with <z:chebi fb="0" ids="31718">ioxaglate</z:chebi> versus saline (2.6 +/- 0.4 mg and 4.7 +/- 0.7 mg, respectively, P&lt; 0.05) whereas TW remained unchanged in the <z:chebi fb="0" ids="31709">iohexol</z:chebi> group (4.2 +/- 0.4 mg) </plain></SENT>
<SENT sid="7" pm="."><plain>The nonionic dimer iodixanol induced a direct vasoconstrictor effect on the carotid artery and was consequently excluded from the study </plain></SENT>
<SENT sid="8" pm="."><plain>(2) Neither iso-osmolar nor hyperosmolar solutions of meglumine had any effect on TTO whereas both <z:chebi fb="199" ids="26708">sodium</z:chebi> and meglumine salts of <z:chebi fb="0" ids="31718">ioxaglic acid</z:chebi> prolonged TTO, suggesting that the antithrombotic effect of <z:chebi fb="0" ids="31718">ioxaglate</z:chebi> is mediated by the <z:chebi fb="0" ids="31718">ioxaglic acid</z:chebi> moiety alone as neither meglumine, osmolality or <z:chebi fb="199" ids="26708">sodium</z:chebi> played a significant role </plain></SENT>
<SENT sid="9" pm="."><plain>(3) A synergistic effect on TTO was found when <z:chebi fb="0" ids="31718">ioxaglate</z:chebi> was associated with <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> whereas no such effect was observed with <z:chebi fb="0" ids="31709">iohexol</z:chebi> </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: These data show a greater in vivo antithrombotic potential for the ionic contrast medium <z:chebi fb="0" ids="31718">ioxaglate</z:chebi> than for the non-ionic contrast medium <z:chebi fb="0" ids="31709">iohexol</z:chebi> and, for the first time, a synergistic effect between a contrast medium and a platelet antiaggregant drug in vivo </plain></SENT>
</text></document>